Pharming Group (PHAR) Financials: Revenue & Earnings
PHAR$12.20-0.06 -0.49%
$855.16M
Market Cap
72.04
P/E
52.04
Forward P/E
47
Score
Pharming Group (PHAR) Financials: Revenue & Earnings
PHAR price $12.20 -0.06 -0.49%
- Ticker
- PHAR
- Price
- $12.20
- Change
- -0.06 -0.49%
- Market cap ?
- $855.16M
- P/E ?
- 72.04
- Forward P/E ?
- 52.04
- Dividend yield ?
- 0.00%
- Beta ?
- 0.09
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 47
- Value
- 49
- Quality
- 58
- Growth
- 34
Stocklytics score rationale: value 49, quality 58, growth 34.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 16693660 | 107517335 | 154575611 | 189389000 | 212174000 | 198871000 | 205622000 | 245316000 | 297200000 | 376134000 |
Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized…
Earnings and financials
Pharming Group N.V. (PHAR) trades at $12.20, with a market cap of $855.16M and a trailing P/E of 72.04. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 16693660 | 107517335 | 154575611 | 189389000 | 212174000 | 198871000 | 205622000 | 245316000 | 297200000 | 376134000 |
Insights · Dividends · Forecast · Financials · Learn